Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03869190 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 272
- Enrollment target
NCT03869190 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 272 participants.
The verdict
NCT03869190, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 272 participants
- Enrollment target
Study Summary
A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status). Participants in the mUC Cohort who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen for Stage 2.
Interventions
- DRUG Atezolizumab
- DRUG Enfortumab Vedotin
- DRUG Niraparib
- DRUG Tiragolumab
- DRUG Magrolimab (Hu5F9-G4)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2025-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03869190
The ClinicalTrials.gov registry entry for NCT03869190 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Atezolizumab is the first listed.
NCT03869190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03869190 about?
NCT03869190 is a clinical study titled "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)". A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new...
What is the current status of trial NCT03869190?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 272 participants. The study started on 2019-06-01. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT03869190?
The interventions under investigation include: Atezolizumab (DRUG), Enfortumab Vedotin (DRUG), Niraparib (DRUG), Tiragolumab (DRUG), Magrolimab (Hu5F9-G4) (DRUG).
Who is sponsoring clinical trial NCT03869190?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.